SMC product assessment decisions

The Scottish Medicines Consortium (SMC) has announced its decision on the following therapies:

ACCEPTED FOR USE

  • Xolair (omalizumab) as add-on therapy in severe persistent allergic asthma.
  • Januvia (sitagliptin) for treatment of type II diabetes mellitus in combination with metformin.
  • Budenofalk (budesonide) for ulcerative colitis of the rectum and sigmoid colon.
  • Invanz (ertapenum) for prophylaxis of surgical site infection following elective colorectal surgery.
  • Atimos Modulite (formoterol) for coronary obstructive pulmonary disease.

REJECTED FOR USE

  • Cipralex (escitalopram) for obsessive compulsive disorder.
  • Prialt (ziconotide) for treatment of severe, chronic pain.
  • Cystadane (betaine) as adjunctive treatment of homocystinuria.

Further information: The Scottish Medicines Consortium

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...

New contraindication for co-cyprindiol

New contraindication for co-cyprindiol

Cyproterone-containing medicines are now contraindicated...

GPs demand clarity on flu vaccination plans for 2020/21

GPs demand clarity on flu vaccination plans for 2020/21

GPs say they are struggling to plan flu vaccine orders...